Salmonella Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type Salmonella Typhimurium infection
Background Development of Salmonella enterica serovar Typhimurium ( S. Typhimurium) live attenuated vaccine carrier strain to prevent enteric infections has been a subject of intensive study. Several mutants of S . Typhimurium have been proposed as an effective live attenuated vaccine strain. Unfort...
Saved in:
Published in | BMC microbiology Vol. 13; no. 1; p. 236 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
22.10.2013
BioMed Central Ltd |
Subjects | |
Online Access | Get full text |
ISSN | 1471-2180 1471-2180 |
DOI | 10.1186/1471-2180-13-236 |
Cover
Loading…
Summary: | Background
Development of
Salmonella enterica
serovar Typhimurium (
S.
Typhimurium) live attenuated vaccine carrier strain to prevent enteric infections has been a subject of intensive study. Several mutants of
S
. Typhimurium have been proposed as an effective live attenuated vaccine strain. Unfortunately, many such mutant strains failed to successfully complete the clinical trials as they were suboptimal in delivering effective safety and immunogenicity. However, it remained unclear, whether the existing live attenuated
S
. Typhimurium strains can further be attenuated with improved safety and immune efficacy or not.
Results
We deleted a specific non-SPI (Salmonella Pathogenicity Island) encoded virulence factor
mig-14
(an antimicrobial peptide resistant protein) in
ssaV
deficient
S.
Typhimurium strain. The
ssaV
is an important SPI-II gene involved in
Salmonella
replication in macrophages and its mutant strain is considered as a potential live attenuated strain. However, fatal systemic infection was previously reported in immunocompromised mice like
Nos2
−/−
and
Il-10
−/−
when infected with
ssaV
deficient
S
. Typhimurium. Here we reported that attenuation of
S
. Typhimurium
ssaV
mutant in immunocompromised mice can further be improved by introducing additional deletion of gene
mig-14
. The
ssaV, mig-14
double mutant was as efficient as
ssaV
mutant, with respect to host colonization and eliciting
Salmonella
-specific mucosal sIgA and serum IgG response in wild-type C57BL/6 mice. Interestingly, this double mutant did not show any systemic infection in immunocompromised mice.
Conclusions
This study suggests that
ssaV, mig-14
double mutant strain can be effectively used as a potential vaccine candidate even in immunocompromised mice. Such attenuated vaccine strain could possibly used for expression of heterologous antigens and thus for development of a polyvalent vaccine strain. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
ISSN: | 1471-2180 1471-2180 |
DOI: | 10.1186/1471-2180-13-236 |